Loading...

We've got a brand new version of Simply Wall St! Try it out

Cynata Therapeutics

ASX:CYP
Snowflake Description

Exceptional growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CYP
ASX
A$136M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The last earnings update was 87 days ago. More info.


Add to Portfolio Compare Print
  • Cynata Therapeutics has significant price volatility in the past 3 months.
CYP Share Price and Events
7 Day Returns
-0.8%
ASX:CYP
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
19.9%
ASX:CYP
50.9%
AU Biotechs
16.3%
AU Market
CYP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cynata Therapeutics (CYP) -0.8% -3.4% -21% 19.9% 66% 250%
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • CYP underperformed the Biotechs industry which returned 50.9% over the past year.
  • CYP outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
CYP
Industry
5yr Volatility vs Market

CYP Value

 Is Cynata Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cynata Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cynata Therapeutics.

ASX:CYP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.4%
Perpetual Growth Rate 10-Year AU Government Bond Rate 2.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for ASX:CYP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year AU Govt Bond Rate 2.3%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.28
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.28 (1 + (1- 30%) (0%))
1.188
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.19
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.31% + (1.188 * 5.96%)
9.39%

Discounted Cash Flow Calculation for ASX:CYP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cynata Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

ASX:CYP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (AUD, Millions) Source Present Value
Discounted (@ 9.39%)
2020 1.80 Analyst x1 1.65
2021 -2.30 Analyst x1 -1.92
2022 17.80 Analyst x1 13.60
2023 30.02 Est @ 68.65% 20.96
2024 44.66 Est @ 48.75% 28.51
2025 60.21 Est @ 34.82% 35.13
2026 75.30 Est @ 25.07% 40.17
2027 89.03 Est @ 18.24% 43.42
2028 101.02 Est @ 13.46% 45.03
2029 111.24 Est @ 10.12% 45.33
Present value of next 10 years cash flows A$271.00
ASX:CYP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= A$111.24 × (1 + 2.31%) ÷ (9.39% – 2.31%)
A$1,607.49
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= A$1,607.49 ÷ (1 + 9.39%)10
A$655.08
ASX:CYP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= A$271.00 + A$655.08
A$926.08
Equity Value per Share
(AUD)
= Total value / Shares Outstanding
= A$926.08 / 103.02
A$8.99
ASX:CYP Discount to Share Price
Calculation Result
Value per share (AUD) From above. A$8.99
Current discount Discount to share price of A$1.30
= -1 x (A$1.30 - A$8.99) / A$8.99
85.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cynata Therapeutics is available for.
Intrinsic value
>50%
Share price is A$1.3 vs Future cash flow value of A$8.99
Current Discount Checks
For Cynata Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cynata Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cynata Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cynata Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cynata Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:CYP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.08
ASX:CYP Share Price ** ASX (2019-11-17) in AUD A$1.3
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cynata Therapeutics.

ASX:CYP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:CYP Share Price ÷ EPS (both in AUD)

= 1.3 ÷ -0.08

-15.27x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cynata Therapeutics is loss making, we can't compare its value to the Global Biotechs industry average.
  • Cynata Therapeutics is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Cynata Therapeutics's expected growth come at a high price?
Raw Data
ASX:CYP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -15.27x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
94.3%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cynata Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cynata Therapeutics's assets?
Raw Data
ASX:CYP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.11
ASX:CYP Share Price * ASX (2019-11-17) in AUD A$1.3
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:CYP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:CYP Share Price ÷ Book Value per Share (both in AUD)

= 1.3 ÷ 0.11

12.03x

* Primary Listing of Cynata Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cynata Therapeutics is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Cynata Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Cynata Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CYP Future Performance

 How is Cynata Therapeutics expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
94.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cynata Therapeutics expected to grow at an attractive rate?
  • Cynata Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Cynata Therapeutics's earnings growth is expected to exceed the Australia market average.
  • Cynata Therapeutics's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:CYP Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:CYP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 94.3%
ASX:CYP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 64%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:CYP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:CYP Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-06-30 37 18 15 1
2021-06-30 15 -2 -2 1
2020-06-30 14 2 3 1
2019-11-18
ASX:CYP Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 1 -7 -8
2019-03-31 1 -6 -7
2018-12-31 1 -5 -6
2018-09-30 1 -4 -5
2018-06-30 1 -4 -5
2018-03-31 1 -4 -5
2017-12-31 1 -5 -5
2017-09-30 2 -4 -5
2017-06-30 2 -4 -5
2017-03-31 2 -3 -4
2016-12-31 2 -2 -3
2016-09-30 1 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cynata Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Cynata Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:CYP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Cynata Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CYP Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-06-30 0.15 0.15 0.15 1.00
2021-06-30 -0.02 -0.02 -0.02 1.00
2020-06-30 0.03 0.03 0.03 1.00
2019-11-18
ASX:CYP Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.08
2019-03-31 -0.07
2018-12-31 -0.06
2018-09-30 -0.06
2018-06-30 -0.05
2018-03-31 -0.06
2017-12-31 -0.06
2017-09-30 -0.06
2017-06-30 -0.06
2017-03-31 -0.05
2016-12-31 -0.05
2016-09-30 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Cynata Therapeutics is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Cynata Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cynata Therapeutics has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CYP Past Performance

  How has Cynata Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cynata Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cynata Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Cynata Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cynata Therapeutics's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Cynata Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cynata Therapeutics Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:CYP Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 1.31 -8.47 1.85 5.65
2019-03-31 1.33 -7.10 1.94 4.44
2018-12-31 1.36 -5.73 2.02 3.22
2018-09-30 1.37 -5.15 1.58 3.22
2018-06-30 1.38 -4.57 1.13 3.22
2018-03-31 1.40 -4.96 1.31 3.35
2017-12-31 1.43 -5.35 1.49 3.47
2017-09-30 1.59 -4.95 1.39 3.47
2017-06-30 1.75 -4.55 1.28 3.47
2017-03-31 1.81 -4.02 0.80 3.81
2016-12-31 1.86 -3.49 0.32 4.16
2016-09-30 1.48 -4.22 0.67 4.16
2016-06-30 1.10 -4.94 1.02 4.16
2016-03-31 1.18 -4.85 1.95 3.04
2015-12-31 1.25 -4.76 2.88 1.92
2015-09-30 0.77 -4.24 2.07 1.92
2015-06-30 0.29 -3.71 1.26 1.92
2015-03-31 0.16 -3.22 1.58 1.21
2014-12-31 0.04 -2.73 1.89 0.50
2014-09-30 0.03 -2.89 1.90 0.50
2014-06-30 0.03 -3.04 1.91 0.50
2014-03-31 0.03 -2.65 1.63 0.30
2013-12-31 0.03 -2.26 1.35 0.09
2013-09-30 0.03 -1.59 0.77 0.09
2013-06-30 0.03 -0.92 0.19 0.09
2013-03-31 0.05 -0.61 0.17 0.08
2012-12-31 0.06 -0.30 0.15 0.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cynata Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cynata Therapeutics has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cynata Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cynata Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cynata Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CYP Health

 How is Cynata Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cynata Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cynata Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cynata Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cynata Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Cynata Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cynata Therapeutics Company Filings, last reported 4 months ago.

ASX:CYP Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 10.97 0.00 6.98
2019-03-31 10.97 0.00 6.98
2018-12-31 15.30 0.00 10.64
2018-09-30 15.30 0.00 10.64
2018-06-30 15.39 0.00 12.21
2018-03-31 15.39 0.00 12.21
2017-12-31 12.25 0.00 8.84
2017-09-30 12.25 0.00 8.84
2017-06-30 13.86 0.00 10.35
2017-03-31 13.86 0.00 10.35
2016-12-31 7.65 0.00 3.91
2016-09-30 7.65 0.00 3.91
2016-06-30 8.58 0.00 4.88
2016-03-31 8.58 0.00 4.88
2015-12-31 10.88 0.00 6.37
2015-09-30 10.88 0.00 6.37
2015-06-30 8.75 0.03 4.70
2015-03-31 8.75 0.03 4.70
2014-12-31 10.81 0.00 6.16
2014-09-30 10.81 0.00 6.16
2014-06-30 9.85 0.00 5.09
2014-03-31 9.85 0.00 5.09
2013-12-31 10.87 0.00 6.20
2013-09-30 10.87 0.00 6.20
2013-06-30 1.64 0.00 1.12
2013-03-31 1.64 0.00 1.12
2012-12-31 2.15 0.00 1.47
  • Cynata Therapeutics has no debt.
  • Cynata Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cynata Therapeutics has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Cynata Therapeutics has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Cynata Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cynata Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CYP Dividends

 What is Cynata Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cynata Therapeutics dividends.
If you bought A$2,000 of Cynata Therapeutics shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cynata Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cynata Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:CYP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:CYP Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2022-06-30
2021-06-30
2020-06-30
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cynata Therapeutics has not reported any payouts.
  • Unable to verify if Cynata Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cynata Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cynata Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cynata Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cynata Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cynata Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CYP Management

 What is the CEO of Cynata Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ross MacDonald
COMPENSATION A$476,917
AGE 61
CEO Bio

Dr. Ross Alexander MacDonald, Ph.D. serves as Member of Investment Committee at Uniseed Pty Limited and also serves as the Chief Executive Officer and Managing Director at Cynata Therapeutics Limited (formerly Eco Quest Limited). Dr. MacDonald served as the Chief Executive Officer of Hatchtech Pty Ltd. since April 26, 2012. He served as the Chief Executive Officer and Managing Director of Living Cell Technologies Ltd., from August 2, 2010 to June 24, 2011. He served as Vice President of Business Development for North America & South Pacific at Sinclair IS Pharma Plc. since November 2008. He served as Vice President of Business Development of Connetics Corporation. He served as Vice President of Research and Development of F H Faulding & Co Limited (now part of Mayne Group Limited). He served as the Managing Director of Soltec Research. He began his career as a Consultant Research Analyst in the pharmaceutical industry. He joined AMRAD Corporation in 1987 and served various positions in business development. He served Vice President of Stiefel Laboratories, Inc. and Connetics Corporation. He has an extensive and successful background in the pharmaceutical industry. He has 18 years local and international experience in unit and general management in the industry, he has brought several products from lab bench to market. He also has broad-based experience in profit centre management, technology commercialization, strategic planning, deal negotiation and transaction (licensing, M&A, asset sale & purchase), market and industry analysis, human resource management, product development and finance. He serves as a Non-Executive Director of Clinical Network Services Pty Ltd. He serves as a Member of Healthcare Group and Licensing Executive Society Australia & New Zealand. He serves as a Non-Executive Director of Telesso Ltd and CNSBio Pty Ltd. He has been an Executive Director of Cynata Therapeutics Limited (Formerly Eco Quest Limited) since August 1, 2013. He serves as a Member of the Medical Advisory Board at Consegna Group Limited. He served as an Independent Non-Executive Director of iSonea Limited since April 3, 2012 until February 4, 2014. He served as a Non-Executive Director at Telesso Technologies Limited (formerly Eiffel Technologies Ltd.) from February 2003 to November 2013. He served as Non-Executive Director of Hatchtech Pty Ltd., since March 2010 until October 31, 2013. He served as a Non-Executive Director of Relevare Pharmaceuticals LTD. (formerly CNSBio Pty Ltd.). He served as a Director of Living Cell Technologies Ltd., from August 2, 2010 to June 24, 2011. Dr. MacDonald holds Ph.D. in Biochemistry from Monash University and Graduate Diploma in Business Administration from Swinburne University.

CEO Compensation
  • Ross's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Ross's remuneration is about average for companies of similar size in Australia.
Management Team

Ross MacDonald

TITLE
MD, CEO & Executive Director
COMPENSATION
A$477K
AGE
61

Kilian Kelly

TITLE
Chief Operating Officer
COMPENSATION
A$449K
TENURE
0.5 yrs

Peter Webse

TITLE
Company Secretary & Non-Executive Director
COMPENSATION
A$100K
AGE
56
TENURE
7.6 yrs
Board of Directors Tenure

Average tenure and age of the Cynata Therapeutics board of directors in years:

6.3
Average Tenure
59
Average Age
  • The tenure for the Cynata Therapeutics board of directors is about average.
Board of Directors

Paul Wotton

TITLE
Non-Executive Chairman
COMPENSATION
A$172K
AGE
59
TENURE
2.8 yrs

Ross MacDonald

TITLE
MD, CEO & Executive Director
COMPENSATION
A$477K
AGE
61
TENURE
6.3 yrs

Peter Webse

TITLE
Company Secretary & Non-Executive Director
COMPENSATION
A$100K
AGE
56
TENURE
7.5 yrs

Stewart Washer

TITLE
Non-Executive Director
COMPENSATION
A$50K
AGE
49
TENURE
6.3 yrs

Igor Slukvin

TITLE
Member of Scientific Advisory Board

Geoff Brooke

TITLE
Independent Non-Executive Director
COMPENSATION
A$52K
AGE
63
TENURE
0.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Cynata Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cynata Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CYP News

Simply Wall St News

The Cynata Therapeutics (ASX:CYP) Share Price Is Up 248% And Shareholders Are Boasting About It

Cynata Therapeutics Limited (ASX:CYP) shareholders might be concerned after seeing the share price drop 23% in the last quarter. … With the share price up 28% per year, over 5 years, the market is seems hopeful about the potential, despite the cash burn. … A Different Perspective Investors in Cynata Therapeutics had a tough year, with a total loss of 7.7%, against a market gain of about 10%.

Simply Wall St -

Analysts Expect Breakeven For Cynata Therapeutics Limited (ASX:CYP)

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. … The AU$122m market-cap posted a loss in its most recent financial year of -AU$4.6m and a latest trailing-twelve-month loss of -AU$5.7m leading to an even wider gap between loss and breakeven. … See our latest analysis for Cynata Therapeutics

Simply Wall St -

What Type Of Shareholder Owns Cynata Therapeutics Limited's (ASX:CYP)?

If you want to know who really controls Cynata Therapeutics Limited (ASX:CYP), then you'll have to look at the makeup of its share registry. … With a market capitalization of AU$120m, Cynata Therapeutics is a small cap stock, so it might not be well known by many institutional investors. … Check out our latest analysis for Cynata Therapeutics

Simply Wall St -

Is Cynata Therapeutics Limited's (ASX:CYP) Balance Sheet Strong Enough To Weather A Storm?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is CYP right in choosing financial flexibility over lower cost of capital … Debt capital generally has lower cost of capital compared to equity funding.

Simply Wall St -

When Will Cynata Therapeutics Limited (ASX:CYP) Breakeven?

Cynata Therapeutics Limited's (ASX:CYP):. … Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. … Check out our latest analysis for Cynata Therapeutics

Simply Wall St -

What does Cynata Therapeutics Limited's (ASX:CYP) Balance Sheet Tell Us About Its Future?

The direct benefit for Cynata Therapeutics Limited (ASX:CYP), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

How Much Of Cynata Therapeutics Limited (ASX:CYP) Do Insiders Own?

If you want to know who really controls Cynata Therapeutics Limited (ASX:CYP), then you'll have to look at the makeup of its share registry. … Cynata Therapeutics is a smaller company with a market capitalization of AU$109m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

Cynata Therapeutics Limited's (ASX:CYP) Profit Outlook

Cynata Therapeutics Limited's (ASX:CYP):. … Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. … The company’s loss has recently broadened since it announced a -AU$4.55m loss in the full financial year, compared to the latest trailing-twelve-month loss of -AU$5.35m, moving it further away from breakeven.

Simply Wall St -

Was Cynata Therapeutics Limited's (ASX:CYP) Earnings Decline Part Of A Broader Industry Downturn?

Analyzing Cynata Therapeutics Limited's (ASX:CYP) track record of past performance is a valuable exercise for investors. … View our latest analysis for Cynata Therapeutics Was CYP's recent earnings decline indicative of a tough track record? … Cynata Therapeutics's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story.

Simply Wall St -

How Confident Are Insiders About Cynata Therapeutics Limited (ASX:CYP)?

Cynata Therapeutics is one of Australia’s small-cap stocks that saw some insider buying over the past three months, with insiders investing in more than 4 million shares during this period. … In the past three months, Cynata Therapeutics’s share price reached a high of A$1.54 and a low of A$0.83. … Next Steps: Cynata Therapeutics’s net buying tells us the stock is in favour with some insiders, which is coherent with the positive growth in expected earnings, as well as the significant share price volatility over the same period of trade.

Simply Wall St -

CYP Company Info

Description

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.

Details
Name: Cynata Therapeutics Limited
CYP
Exchange: ASX
Founded: 2011
A$135,983,961
103,018,153
Website: http://www.cynata.com
Address: Cynata Therapeutics Limited
62 Lygon Street,
Level 3,
Carlton,
Victoria, 3053,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX CYP Ordinary Shares Australian Securities Exchange AU AUD 20. Dec 2007
OTCPK CYYN.F Ordinary Shares Pink Sheets LLC US USD 20. Dec 2007
DB 51S Ordinary Shares Deutsche Boerse AG DE EUR 20. Dec 2007
CHIA CYP Ordinary Shares Chi-X Australia AU AUD 20. Dec 2007
Number of employees
Current staff
Staff numbers
0
Cynata Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:34
End of day share price update: 2019/11/17 00:00
Last estimates confirmation: 2019/10/17
Last earnings filing: 2019/08/23
Last earnings reported: 2019/06/30
Last annual earnings reported: 2019/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.